Xsolla Expands Its Commitment to LATAM Game Development With the Journey of Indies (JOIN) Program
25.3.2025 14:00:00 CET | Business Wire | Press Release
Xsolla, a leading global video game commerce company, is proud to announce the launch of the Journey of Indies (JOIN) Program, powered by Xsolla. This LATAM-focused initiative is designed to help indie and mid-tier game developers scale their businesses with commercialization tools, mentorship, and industry partnerships. By integrating developers into Xsolla's ecosystem of commercialization tools, this program aims to drive innovation, expand opportunities, and generate new revenue streams.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250325229062/en/
Graphic: Xsolla
Key Dates:
- March 25: Livestream announcing the JOIN Program at 5 PM ET.
- April 7: Accelerator begins to go live.
- April 25: Official hub opening in the city of Brasilia.
- April 30: Gamescom LATAM panel on the accelerator program in Brazil.
- June 22-26: B2B Innova Summit event in Brasilia.
In collaboration with Institutio Conecta and Indie Hero, the initiative will leverage a grant provided by the Secretariat of Science, Technology, and Innovation of the Federal District (SECTI-DF) to establish a video game hub in Brasilia. This hub will provide a dedicated space for education, business development, and hands-on commercialization training. The JOIN Program aligns with game developers’ associations, industry stakeholders, and public/private entities to unlock the region’s creative potential.
The Journey of Indies (JOIN) Program powered by Xsolla, is designed to address the unique challenges faced by indie and mid-tier developers in LATAM, offering structured support through:
- Exclusive One-Year Access to Educational Programs— Indie Hero will distribute JOIN’s educational content across Brazil, ensuring developers gain valuable insights into game business strategies.
- Mentorship & Talent Selection— JOIN will support selecting top candidates for various acceleration paths, helping developers refine their projects and business models.
- Hands-On Commercialization Training— Participants will gain a general knowledge of monetization and distribution, extending beyond just Xsolla’s tools. They will also learn to integrate Xsolla’s solutions into their go-to-market strategies.
- Industry-Wide Collaboration— Through Indie Hero’s extensive network of game associations and guilds across Brazil, the program will expand its reach and impact.
- Publishing & Distribution Support— Indie Hero’s publishing label, GoGo Games Interactive, will assist developers in seamlessly onboarding to Xsolla’s ecosystem.
“LATAM is one of the most promising and rapidly growing regions for game development,” said Chris Hewish, Chief Strategy Officer at Xsolla. “By partnering with key industry players and investing in local talent, we’re committed to providing the necessary resources and knowledge to help developers turn their creative visions into successful businesses.”
The Journey of Indies (JOIN) Program is now open for applications. Indie and mid-tier studios across LATAM are encouraged to apply and take advantage of this unparalleled opportunity to scale their businesses with Xsolla’s expertise.
For more information and to apply, visit: https://xsolla.pro/p6i
About Xsolla
Xsolla is a leading global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in London, Berlin, Seoul, Beijing, Kuala Lumpur, Raleigh, Tokyo, Montreal, and cities around the world.
For more information, visit xsolla.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250325229062/en/
Contacts
Media Contact
Derrick Stembridge
Vice President of Global Public Relations, Xsolla
d.stembridge@xsolla.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom